Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Moves To Add Indications For Velcade Blood-Cancer Drug

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical, new owner of U.S.-based Millennium Pharmaceuticals, plans to expand the approved indications for the subsidiary's Velcade (bortezomib) drug for multiple myeloma. Millennium's patent for the drug expires in the United States in 2017 and Takeda wants to extend its market life by seeking new uses for Velcade, such as for treating lymphomas. The drug is in Phase III trials for two types of lymphoma, non-Hodgkin for which it plans to apply by 2011, and mantle cell in 2012. On its own, Millennium is developing the drug as a subcutaneous injection, instead of its current venous form, and expects to seek approval for it in 2011. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071771

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel